Drugs / CNP-201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05250856 | Mar 2022 → Dec 2023 | food allergy | COUR Pharmaceutical Development Company, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04950504 | Jun 2021 → Jun 2022 | food allergy | COUR Pharmaceutical Development Company, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNP-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04950504 ↗ |
| Route | Intravenous | “each cohort of four (4) subjects will receive CNP-201 by intravenous (IV) infusion on Days #1 and #8” NCT05250856 ↗ |